Core Insights - Tapestry, Inc. reported fourth-quarter adjusted earnings of $1.04 per share, exceeding the consensus estimate of $1.02, with revenue of $1.72 billion, reflecting an 8% year-over-year increase and surpassing expectations [1] - The company anticipates fiscal 2026 revenue to approach $7.2 billion, slightly above the previous estimate of $6.96 billion, indicating low-single-digit growth from the prior year [2] Financial Performance - Coach experienced strong handbag revenue growth, attributed to a mid-teens average unit retail (AUR) gain for the quarter and a low-double-digit gain for the year [1] - Telsey Advisory Group analyst Dana Telsey maintains an Outperform rating on Tapestry's stock, with a price target of $125 [2] Earnings Outlook - The earnings outlook considers current mitigation efforts, with Telsey suggesting that the guidance appears conservatively prudent, indicating potential for upside [3] - The company is optimistic about a strong start to fiscal year 2026, with a higher dividend enhancing confidence ahead of the upcoming Investor Day [3] Tariff Impact - Tapestry faces greater tariff pressure than expected, with the early end of the de minimis exemption leading to a combined $160 million profit impact, equating to a 230 basis points hit on margins [4] - This situation results in a 60-cent EPS drag, most of which was not present in the previous quarter, due to the exemption's unexpected early termination [4] Revenue Projections - For fiscal year 2026, the analyst projects revenue of $7.24 billion, a 3.2% increase from the prior estimate of $6.99 billion, aligning with the guidance of "approaching $7.2 billion" [5] - The expectation is that Coach will outperform while Kate Spade may underperform earlier forecasts [5] Stock Performance - Tapestry shares are trading higher by 2.90%, reaching $98.50 [5]

Company Performance - OrganiGram reported a quarterly loss of $0.03 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.01, marking an earnings surprise of -200.00% [1] - The company posted revenues of $51.16 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.86%, and showing a significant increase from $30.01 million in the same quarter last year [2] - Over the last four quarters, OrganiGram has not surpassed consensus EPS estimates, but it has topped consensus revenue estimates three times [2] Stock Performance - OrganiGram shares have declined approximately 1.2% since the beginning of the year, contrasting with the S&P 500's gain of 9.6% [3] - The current Zacks Rank for OrganiGram is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $49.86 million, and for the current fiscal year, it is $0.07 on revenues of $170.56 million [7] - The trend of estimate revisions for OrganiGram was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Products industry, to which OrganiGram belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may impact the stock's performance [8] - The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]

Company Performance - Gauzy Ltd. reported a quarterly loss of $0.66 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.40, representing an earnings surprise of -65.00% [1] - The company posted revenues of $20.05 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 30.75%, compared to revenues of $24.41 million a year ago [2] - Over the last four quarters, Gauzy Ltd. has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [2] Stock Movement and Outlook - Gauzy Ltd. shares have declined approximately 34.8% since the beginning of the year, while the S&P 500 has gained 9.6% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.14 for the coming quarter and -$0.73 for the current fiscal year [7] Industry Context - The Electronics - Miscellaneous Products industry, to which Gauzy Ltd. belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Gauzy Ltd.'s stock performance [5]

Company Performance - WideOpenWest reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, and compared to a loss of $0.13 per share a year ago, indicating an earnings surprise of -46.67% [1] - The company posted revenues of $144.2 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.14%, but down from $158.8 million in the same quarter last year [2] - Over the last four quarters, WideOpenWest has surpassed consensus EPS estimates only once, while it has topped consensus revenue estimates three times [2] Stock Performance - WideOpenWest shares have declined approximately 35.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $141.3 million, and for the current fiscal year, it is -$0.78 on revenues of $574.9 million [7] Industry Outlook - The Cable Television industry, to which WideOpenWest belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, suggesting a challenging environment for the company [8] - The performance of WideOpenWest's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Agenus reported a quarterly loss of $1 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.78, but an improvement from a loss of $2.52 per share a year ago [1] Financial Performance - The company posted revenues of $25.7 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 2.68% and showing an increase from $23.51 million in the same quarter last year [2] - Over the last four quarters, Agenus has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Agenus shares have increased approximately 75.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] Future Outlook - The company's earnings outlook will be crucial for determining the sustainability of its stock price movement, with current consensus EPS estimate for the coming quarter at -$0.20 on revenues of $24.97 million, and for the current fiscal year at $1.56 on revenues of $246.08 million [7] - The estimate revisions trend for Agenus was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Agenus belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Company Performance - Enanta Pharmaceuticals reported a quarterly loss of $0.85 per share, which was better than the Zacks Consensus Estimate of a loss of $1.25, representing an earnings surprise of +32.00% [1] - The company posted revenues of $18.31 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 21.29% and showing an increase from $17.97 million in the same quarter last year [2] - Over the last four quarters, Enanta has surpassed consensus EPS estimates two times and topped revenue estimates twice [2] Stock Movement and Outlook - Enanta Pharmaceuticals shares have increased by approximately 20% since the beginning of the year, outperforming the S&P 500's gain of 8.6% [3] - The future performance of the stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$1.21 on revenues of $15.35 million, and for the current fiscal year, it is -$4.33 on revenues of $62.35 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Enanta belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Enanta's stock may also be influenced by the overall outlook for the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Core Viewpoint - Core Scientific, Inc. reported a quarterly loss of $0.04 per share, outperforming the Zacks Consensus Estimate of a loss of $0.07, indicating a positive earnings surprise of +42.86% [1] - The company generated revenues of $78.63 million for the quarter ended June 2025, which was 2.28% below the Zacks Consensus Estimate and a significant decrease from $141.1 million in the same quarter last year [2] Financial Performance - Over the last four quarters, Core Scientific has exceeded consensus EPS estimates three times and topped revenue estimates twice [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $111.86 million, while for the current fiscal year, the estimate is $1.44 on revenues of $412.08 million [7] Market Position - Core Scientific shares have increased by approximately 2.1% since the beginning of the year, underperforming compared to the S&P 500's gain of 7.8% [3] - The company currently holds a Zacks Rank of 3 (Hold), suggesting that its shares are expected to perform in line with the market in the near future [6] Industry Outlook - The Financial - Miscellaneous Services industry, to which Core Scientific belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Core Scientific's stock performance [5]

Company Performance - Morgan Stanley Direct Lending Fund reported quarterly earnings of $0.5 per share, missing the Zacks Consensus Estimate of $0.52 per share, and down from $0.63 per share a year ago, representing an earnings surprise of -3.85% [1] - The company posted revenues of $99.51 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.29%, and down from $104.19 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - Morgan Stanley Direct Lending Fund shares have lost about 10.8% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The current status of estimate revisions translates into a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the coming quarter is $0.52 on revenues of $98.69 million, and for the current fiscal year, it is $2.08 on revenues of $396.8 million [7] - The outlook for the industry can significantly impact the stock's performance, with the Financial - SBIC & Commercial Industry currently in the bottom 42% of Zacks industries [8]

Willdan Group (WLDN) came out with quarterly earnings of $1.5 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +108.33%. A quarter ago, it was expected that this energy efficiency and sustainability consultant would post earnings of $0.44 per share when it actually produced earnings of $0.63, delivering a surprise of +43.18%.O ...

Group 1: Earnings Performance - Warner Bros. Discovery reported quarterly earnings of $0.63 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.16 per share, and improving from a loss of $4.07 per share a year ago [1] - The earnings surprise was +493.75%, contrasting with a previous quarter where the company had a loss of $0.18 per share against an expected loss of $0.12, resulting in a surprise of -50% [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [2] Group 2: Revenue Performance - The company posted revenues of $9.81 billion for the quarter ended June 2025, which missed the Zacks Consensus Estimate by 0.15%, but showed an increase from year-ago revenues of $9.71 billion [3] - Warner Bros. Discovery has not been able to beat consensus revenue estimates over the last four quarters [3] Group 3: Stock Performance and Outlook - Warner Bros. Discovery shares have increased by approximately 21% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [4] - The future performance of the stock will depend on management's commentary during the earnings call and the company's earnings outlook [4][5] - The current consensus EPS estimate for the coming quarter is $0.17 on revenues of $9.25 billion, and for the current fiscal year, it is -$0.04 on revenues of $37.91 billion [8] Group 4: Industry Context - The Broadcast Radio and Television industry, to which Warner Bros. Discovery belongs, is currently ranked in the bottom 39% of over 250 Zacks industries, indicating potential challenges ahead [9] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Warner Bros. Discovery's stock performance [6]